Recommended

Alzheimer’s IV maintenance treatment gains UK approval
Merck furthers manufacturing sustainability commitment in South Korea
FDA replaces George Tidmarsh with new CDER Director
Roche multiple sclerosis drug shows best-in-disease potential
Novartis inaugurates new US radioligand manufacturing facility
Pfizer beats Novo Nordisk in Metsera obesity biopharma offer
Stem cell research illustrates large-scale iPSC platelet manufacturing potential
CRDMO BioDuro recruits new global president, CMC
news

Johnson & Johnson targets oncology portfolio with $3bn Halda acquisition

0
SHARES

Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.

Johnson & Johnson Halda Therapeutics

Credit: Michael Vi / Shutterstock.com

Johnson & Johnson has agreed to acquire US-based biotech Halda Therapeutics for $3.1 billion, giving it access to a pipeline of highly targeted oral treatments for multiple solid cancers.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The deal includes Halda’s lead candidate, HLD-0915, a potential first-in-class prostate cancer therapy. Its novel precision approach means it can eradicate cancer cells and overcome mechanisms of treatment resistance.

Dr John Reed, PhD, Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson, said: “Results seen with HLD-0915 demonstrate impressive preliminary efficacy and a strong early safety profile in prostate cancer.”

This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth”

He emphasised the potential of this data, as “many therapies lose effectiveness over time due to resistance [so]… we are eager to accelerate the ongoing phase I/II clinical trial of HLD-0915 and progress a pipeline of novel product candidates based on [Regulated Induced Proximity TArgeting Chimer] RIPTAC technology.”

Christian Schade, President and CEO, of Halda explained the company is committed to advancing this technology “to develop the next generation of selective, proximity-based small molecule therapeutics for patients with serious diseases”.

Halda’s portfolio also includes earlier candidates for breast, lung and multiple other tumour types, which Johnson & Johnson also acquires.

Advancing precision cancer medicine

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, said: “This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth.”

The transaction is expected to close within the next few months, subject to customary closing conditions.

This announcement comes two months after Roche made a similarly-priced acquisition with another US-based firm, this time with the aim to advance a potential best-in-disease obesity therapy.

Share via
Share via